cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Amicus Therapeutics Inc
11 own
23 watching
Current Price
$13.25
$-0.26
(-1.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
3,721.75M
52-Week High
52-Week High
13.615
52-Week Low
52-Week Low
5.91
Average Volume
Average Volume
1.66M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization3,721.75M
icon52-Week High13.615
icon52-Week Low5.91
iconAverage Volume1.66M
iconDividend Yield--
iconP/E Ratio--
What does the Amicus Therapeutics Inc do?
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Read More
How much money does Amicus Therapeutics Inc make?
News & Events about Amicus Therapeutics Inc.
Globe Newswire
1month ago
CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data CHMP Recommends Label for Long-Term Enzyme Replacement Therapy in Combination with Miglustat for both ERT-Experienced and Treatment-Nave Adults Living with Late-Onset Pompe Disease CHMP Opinion...
Ticker Report
1month ago
StockNews.com lowered shares of Amicus Therapeutics (NASDAQ:FOLD Get Rating) from a buy rating to a hold rating in a report released on Wednesday morning. Separately, Morgan Stanley upped their price target on Amicus Therapeutics from $14.00 to $15.00 and gave the stock an equal weight ...
Ticker Report
2 months ago
Amicus Therapeutics, Inc. (NASDAQ:FOLD Get Rating) Investment analysts at SVB Leerink reduced their Q4 2023 earnings per share (EPS) estimates for shares of Amicus Therapeutics in a note issued to investors on Monday, November 7th. SVB Leerink analyst J. Schwartz now expects that the...
Globe Newswire
3 months ago
PHILADELPHIA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided an EU regulatory update for AT-GAA. Earlier this morning, the Committee for...
Zolmax
7 months ago
Amicus Therapeutics, Inc. (NASDAQ:FOLD Get Rating) COO Bradley L. Campbell sold 16,410 shares of the firms stock in a transaction that occurred on Tuesday, June 21st. The stock was sold at an average price of $10.00, for a total transaction of $164,100.00. Following the transaction, ...
Frequently Asked Questions
Frequently Asked Questions
What is Amicus Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Amicus Therapeutics Inc shares?
plus_minus_icon
How can I buy Amicus Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Amicus Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Amicus Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Amicus Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Amicus Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Amicus Therapeutics Inc?
plus_minus_icon
What percentage is Amicus Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Amicus Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$13.25
$-0.26
(-1.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00